|
24 November 2017 |
Futura Medical plc
("Futura" or "the Company")
Block Listing Update
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology makes the following update on its block listing, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over ordinary shares of 0.2 pence each.
The table below provides further detail.
|
Name of company: |
Futura Medical plc |
|
|
Name of scheme: |
Unapproved Share Option Scheme ("USOS") |
|
|
Period of return: |
From: |
25 May 2017 |
|
To: |
24 November 2017 |
|
|
Number and class of securities not issued under the scheme(s) at start of period |
USOS: |
2,446,110 |
|
EMI: |
3,021,390 |
|
|
Total: |
5,467,500 |
|
|
Number of securities issued under the scheme(s) during the period Number of securities lapsed under the scheme(s) during the period |
USOS: |
- |
|
EMI: USOS: EMI: |
- 50,000 350,000 |
|
|
Balance under the scheme(s) of securities not yet issued at the end of the period |
USOS: |
2,396,110 |
|
EMI: |
2,671,390 |
|
|
Total: |
5,067,500 |
|
|
Number and class of securities originally admitted and the date of admission |
USOS: |
814,424 on 25 May 2011, 1,202,280 on 8 October 2013, 1,466,208 on 25 May 2017 |
|
USOS Total: |
3,482,912 |
|
|
EMI: |
1,520,576 on 25 May 2011, 1,467,720 on 8 October 2013 1,893,792 on 25 May 2017 |
|
|
EMI Total: |
4,882,088 |
|
|
Total: |
8,365,000 |
|
|
Name of contact: |
Derek Martin, Chief Financial Officer |
|
|
Telephone number of contact: |
+44 (0) 1483 685 670 |
|
For further information please contact:
|
Futura Medical plc |
|
|
James Barder, Chief Executive |
Tel: +44 (0) 1483 685 670 |
|
Email to: james.barder@futuramedical.com |
|
|
N+1 Singer (Nominated Adviser and Broker) |
|
|
Aubrey Powell / Liz Yong Corporate Finance |
Tel:+44 (0) 20 7496 3000 |
|
For media enquiries please contact: |
|
|
Buchanan |
|
|
Mark Court / Sophie Cowles / Stephanie Watson |
Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
This information is provided by RNS